# A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05318573/  
OnCo record `nct05318573` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Fujifilm Pharmaceuticals U.S.A., Inc., active and no longer recruiting.

## Summary

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05318573 by Fujifilm Pharmaceuticals U.S.A., Inc., with 120 participants planned, started 2022-06-01 and due to reach its primary completion in 2029-05. Interventions recorded: Pembrolizumab, FF-10832. Conditions listed: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05318573
- Phase: 2
- Setting: A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05318573: https://clinicaltrials.gov/study/NCT05318573

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05318573.json